Leadership & Pay ·
Eupraxia Pharmaceuticals announced executive leadership changes and an operational restructuring on July 13, 2026
EPRXEupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals announced executive leadership changes and an operational restructuring on July 13, 2026. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, effective July 13, 2026, while Dr. Alex Therien assumed leadership of Research & Development. Amanda Malone stepped down as Chief Scientific and Operating Officer on July 10, 2026. The company transitioned its operations from Victoria to a two-hub structure in Vancouver and Seattle to support clinical growth, with the CEO and key clinical, manufacturing, and commercial leadership based in Seattle. Eupraxia Pharmaceuticals is a biotechnology company focused on clinical and commercial development.